Multiple Sclerosis Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif
Links shared publicly online about this topic.
- 1,286total visits
Multiple Sclerosis Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed
View full resource at medicalnewstoday.com
Tags: Multiple Sclerosis, Multiple Sclerosis Medication, Copaxone, Rebif, Biogen Idec, Elan Corp.
Most Recently Shared on March 26, 2010 at 4:10 pm By:
Multiple Sclerosis Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif http://mnt.to/3ztw #clinicaltrials
Advertisement
